By learning from the cutting-edge nanotechnology, some nanostrategies, including markedly improving the tumor-targeting efficiency of Pt drugs (e.g., OXA, CP, and prodrugs) and delivering anti-ROS agents (e.g., antioxidant drugs and inorganic NPs), have been developed to prevent and/or treat PIPN. This evidence concerns the gene CP and neoplasm.